HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 315 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,778,866 | +2.4% | 674,839 | -3.3% | 0.01% | +14.3% |
| Q2 2023 | $25,175,324 | +5.8% | 697,957 | +12.0% | 0.01% | 0.0% |
| Q1 2023 | $23,805,218 | -9.4% | 623,336 | +34.9% | 0.01% | -12.5% |
| Q4 2022 | $26,287,917 | +5.4% | 462,002 | -26.8% | 0.01% | 0.0% |
| Q3 2022 | $24,943,000 | +248.1% | 630,837 | +287.4% | 0.01% | +300.0% |
| Q2 2022 | $7,165,000 | -59.1% | 162,839 | -62.9% | 0.00% | -50.0% |
| Q1 2022 | $17,514,000 | -9.5% | 439,165 | -8.7% | 0.00% | -20.0% |
| Q4 2021 | $19,350,000 | -64.8% | 481,235 | -64.4% | 0.01% | -58.3% |
| Q3 2021 | $55,021,000 | +6.0% | 1,352,527 | +18.4% | 0.01% | +9.1% |
| Q2 2021 | $51,889,000 | +13.0% | 1,142,674 | +3.7% | 0.01% | +10.0% |
| Q1 2021 | $45,925,000 | -6.8% | 1,101,570 | -4.5% | 0.01% | -16.7% |
| Q4 2020 | $49,257,000 | +44.6% | 1,153,273 | -11.1% | 0.01% | +33.3% |
| Q3 2020 | $34,075,000 | +5.2% | 1,296,577 | +7.3% | 0.01% | 0.0% |
| Q2 2020 | $32,401,000 | +62.3% | 1,208,556 | +8.9% | 0.01% | +28.6% |
| Q1 2020 | $19,964,000 | +13.5% | 1,109,718 | +10.9% | 0.01% | +40.0% |
| Q4 2019 | $17,584,000 | +16.6% | 1,000,242 | +2.9% | 0.01% | +25.0% |
| Q3 2019 | $15,083,000 | -11.3% | 972,470 | -1.7% | 0.00% | -20.0% |
| Q2 2019 | $17,001,000 | +134.7% | 989,538 | +120.0% | 0.01% | +150.0% |
| Q1 2019 | $7,243,000 | +4.2% | 449,798 | -5.3% | 0.00% | 0.0% |
| Q4 2018 | $6,950,000 | -25.4% | 475,059 | -7.3% | 0.00% | -33.3% |
| Q3 2018 | $9,312,000 | +3.0% | 512,554 | -4.3% | 0.00% | 0.0% |
| Q2 2018 | $9,038,000 | +38.1% | 535,697 | +60.3% | 0.00% | +50.0% |
| Q1 2018 | $6,546,000 | +3.8% | 334,190 | +7.4% | 0.00% | 0.0% |
| Q4 2017 | $6,307,000 | +12.3% | 311,282 | -3.7% | 0.00% | 0.0% |
| Q3 2017 | $5,618,000 | +26.1% | 323,388 | -10.4% | 0.00% | +100.0% |
| Q2 2017 | $4,456,000 | +13.2% | 360,868 | +18.9% | 0.00% | 0.0% |
| Q1 2017 | $3,935,000 | +60.7% | 303,626 | +22.5% | 0.00% | 0.0% |
| Q4 2016 | $2,449,000 | +4.3% | 247,907 | +27.7% | 0.00% | 0.0% |
| Q3 2016 | $2,347,000 | +56.1% | 194,197 | -56.3% | 0.00% | 0.0% |
| Q2 2016 | $1,504,000 | -16.9% | 444,091 | +6.0% | 0.00% | 0.0% |
| Q1 2016 | $1,810,000 | -22.6% | 418,923 | +210.2% | 0.00% | 0.0% |
| Q4 2015 | $2,340,000 | +30.3% | 135,054 | +1.0% | 0.00% | 0.0% |
| Q3 2015 | $1,796,000 | -38.9% | 133,687 | +2.7% | 0.00% | 0.0% |
| Q2 2015 | $2,939,000 | +2.3% | 130,188 | -33.5% | 0.00% | 0.0% |
| Q1 2015 | $2,872,000 | +346.0% | 195,772 | +193.5% | 0.00% | – |
| Q4 2014 | $644,000 | +6.1% | 66,705 | +0.1% | 0.00% | – |
| Q3 2014 | $607,000 | -10.9% | 66,653 | -3.3% | 0.00% | – |
| Q2 2014 | $681,000 | +66.9% | 68,908 | +114.8% | 0.00% | – |
| Q1 2014 | $408,000 | -2.2% | 32,081 | +15.2% | 0.00% | – |
| Q4 2013 | $417,000 | +92.2% | 27,851 | +41.7% | 0.00% | – |
| Q3 2013 | $217,000 | -40.9% | 19,650 | -57.4% | 0.00% | – |
| Q2 2013 | $367,000 | – | 46,143 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |